Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19

CompletedOBSERVATIONAL
Enrollment

144

Participants

Timeline

Start Date

May 15, 2020

Primary Completion Date

April 30, 2023

Study Completion Date

July 30, 2023

Conditions
COVID-19SARS-CoV-2 Infection
Interventions
DIAGNOSTIC_TEST

Lung Function tests

Spirometry before and after bronchodilator, lung volumes by body plethysmography, lung diffusion capacity of carbon monoxide (DLCO), respiratory system resistance by impulse oscillometry (IOS)

DIAGNOSTIC_TEST

Exercise capacity

6-minute walk test (6MWT distance)

DIAGNOSTIC_TEST

Exercise physiology

Cardiopulmonary exercise test (CPET)

DIAGNOSTIC_TEST

Health-related quality of life

Short-Form Health Survey Questionnaire (SF-36)

DIAGNOSTIC_TEST

Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening

"1. Adapted translation American Thoracic Society respiratory symptoms questionnaire;~2. Beck Anxiety Inventory (BAI) and Beck's depression Inventory (BDI);~3. Questionnaire for screening for post-traumatic stress symptoms (PTSD)."

Trial Locations (5)

99052-900

Universidade de Passo Fundo, Passo Fundo

90035-000

Hospital Moinhos de Vento, Porto Alegre

90035-003

Hospital de Clínicas de Porto Alegre/Universidade Federal do Rio Grande do Sul, Porto Alegre

90050-170

Univesidade de Ciências da Saúde de Porto Alegre, Porto Alegre

91350-200

Hospital Nossa Senhora da Conceição, Porto Alegre

All Listed Sponsors
collaborator

Hospital de Clinicas de Porto Alegre

OTHER

collaborator

Conselho Nacional de Desenvolvimento Científico e Tecnológico

OTHER_GOV

collaborator

Hospital Moinhos de Vento

OTHER

collaborator

Federal University of Health Science of Porto Alegre

OTHER

collaborator

Universidade de Passo Fundo

OTHER

collaborator

Hospital Nossa Senhora da Conceicao

OTHER

lead

Federal University of Rio Grande do Sul

OTHER

NCT04410107 - Lung Function, Exercise Capacity and Health-Related Quality of Life After Severe COVID-19 | Biotech Hunter | Biotech Hunter